Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stake Lessened by Doheny Asset Management CA

Doheny Asset Management CA cut its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.6% in the 4th quarter, HoldingsChannel reports. The fund owned 22,578 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the period. Doheny Asset Management CA’s holdings in Halozyme Therapeutics were worth $834,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Advisors Asset Management Inc. lifted its position in shares of Halozyme Therapeutics by 0.6% in the 3rd quarter. Advisors Asset Management Inc. now owns 45,598 shares of the biopharmaceutical company’s stock valued at $1,742,000 after acquiring an additional 287 shares in the last quarter. First Horizon Advisors Inc. lifted its position in shares of Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 293 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Halozyme Therapeutics by 2.6% in the 3rd quarter. Fifth Third Bancorp now owns 12,262 shares of the biopharmaceutical company’s stock valued at $468,000 after acquiring an additional 308 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Halozyme Therapeutics by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company’s stock valued at $619,000 after acquiring an additional 347 shares in the last quarter. Finally, Truist Financial Corp lifted its position in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. Truist Financial Corp now owns 102,622 shares of the biopharmaceutical company’s stock valued at $3,793,000 after acquiring an additional 563 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a research report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday. The Goldman Sachs Group cut their target price on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, January 18th. TheStreet downgraded shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. Finally, StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $53.29.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $39.55, for a total transaction of $395,500.00. Following the transaction, the senior vice president now owns 156,558 shares in the company, valued at approximately $6,191,868.90. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 30,000 shares of company stock worth $1,196,800 in the last 90 days. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Stock Up 1.3 %

Shares of HALO traded up $0.50 during mid-day trading on Thursday, hitting $39.80. 347,220 shares of the company’s stock were exchanged, compared to its average volume of 1,206,923. The firm has a fifty day moving average of $40.00 and a two-hundred day moving average of $37.86. Halozyme Therapeutics, Inc. has a twelve month low of $29.85 and a twelve month high of $45.00. The stock has a market cap of $5.06 billion, a price-to-earnings ratio of 18.63, a P/E/G ratio of 0.44 and a beta of 1.26. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.